Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CTH | P32929 | 1/20 | 0.41 |
| ▸ | CBS | P35520 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405410 | 1.00 | CES2 (0.44) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL22922164 | 0.97 | CES2 (0.48) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL10001230 | 0.97 | CES2 (0.46) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL20534923 | 0.95 | EPHX2 (0.42) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL20535086 | 0.95 | CES2 (0.46) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL23405393 | 0.95 | CES2 (0.46) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL7713583 | 0.94 | CES2 (0.50) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL18660231 | 0.94 | CES2 (0.50) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL19875980 | 0.88 | MEN1 (0.50) | CES2EPHX2CYP2C19TSHRCTH | |
| SCHEMBL20579266 | 0.88 | EPHX2 (0.39) | CES2EPHX2CYP2C19TSHRCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118903087-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114126593-B | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4003314-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11267778-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-114126593-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful for preventing or treating disease | 埃斯佩尔维塔治疗股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CES2 989/4885EPHX2 1224/4885CYP2C19 1034/4885 |
| US-11267778-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | CES2 995/4885EPHX2 1239/4885CYP2C19 1045/4885 |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CES2 995/4885EPHX2 1239/4885CYP2C19 1045/4885 |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | CES2 1639/4885EPHX2 690/4885CYP2C19 383/4885 |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | CES2 995/4885EPHX2 1239/4885CYP2C19 1045/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | CES2 963/4885EPHX2 1276/4885CYP2C19 1088/4885 |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CES2 995/4885EPHX2 1239/4885CYP2C19 1045/4885 |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CES2 989/4885EPHX2 1224/4885CYP2C19 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.